Efficacy
Consistent results anywhere on the body with foam and cream from head to toe1,2
Study Design
Study Design
ZORYVE foam 0.3% once daily was studied in 736 patients with plaque psoriasis of the body and scalp1,3-5:
ARRECTOR
Trial 204
Mild to severe plaque psoriasis of the scalp and body (S-IGA ≥3/B-IGA ≥2)
BSA up to 25% (range: 1%-25%, mean: 7%)
76% of patients reported itch with a baseline SI-NRS of ≥4 and 73% had a baseline WI-NRS of ≥4
No concomitant therapies or moisturizers/emollients were allowed on treated areas
PRIMARY ENDPOINT
S-IGA Success at Week 81
Achievement of an S-IGA score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
B-IGA Success at Week 81
(secondary endpoint in Trial 204)
Achievement of a B-IGA score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
KEY SECONDARY ENDPOINTS
(IN ARRECTOR)
SI-NRS Success at Weeks 2, 4 and 83
Achievement of a reduction of a ≥4 point improvement from baseline in patients with baseline score ≥4
WI-NRS Success at Weeks 2, 4 and 83
Achievement of a ≥4-point improvement from baseline in patients with baseline score ≥4
Clearance Rates
POWERFUL SKIN CLEARANCE ANYWHERE DISEASE PRESENTS1
Primary Endpoint S-IGA Success
Primary Endpoint B-IGA Success
63% of patients achieved scalp clearance
at Week 8 vs vehicle1,5
Data are pooled analyses of the ARRECTOR and Trial 204 studies.
In ARRECTOR
40%
of patients achieved complete scalp clearance (S-IGA=0) at Week 8 with ZORYVE foam (n=281) vs 9% with vehicle (n=151)3‡
‡P<0.001 vs vehicle.
See Before & After Photos
42% of patients achieved body clearance at Week 8
vs vehicle1,5
Data are pooled analyses of the ARRECTOR and Trial 204 studies.
In ARRECTOR
28%
of patients achieved complete clearance (B-IGA=0) at Week 8 with ZORYVE foam (n=281) vs 11% with vehicle (n=151) in ARRECTOR3‡
‡P<0.0001 vs vehicle.
See Before & After Photos
Patients experienced IMPROVED CLINICAL SIGNS with ZORYVE in ARRECTOR
7/10 (71%) had PSSI-75 improvement at Week 8 vs 31% with vehicle6
Half (50%) had PASI-75 improvement at Week 8 vs 17% with vehicle6
PSSI-75 and PASI-75 response rates ZORYVE n=281 and vehicle n=151. PSSI-75 and PASI-75 response rates are defined as percentage or patients with 75% improved PSSI and PASI scores from baseline to Week 8. PASI scores evaluate the following plaque psoriasis symptoms: erythema, skin thickness (induration), and desquamation (scaling).
Itch Relief
RAPID ITCH RELIEF1,3
KEY SECONDARY ENDPOINT SI-NRS Success
KEY SECONDARY ENDPOINT WI-NRS Success
In ARRECTOR, 65% of patients experienced
significant scalp itch relief at Week 8 vs vehicle1,3
Greater itch improvement experienced within 24 hours after first application across the scalp and body with ZORYVE vs vehicle (both SI-NRS and WI-NRS, P<0.05)7||
||Measured by mean change from first application in daily SI-NRS/WI-NRS. P-value for WI-NRS is nominal.
In ARRECTOR, 63% of patients experienced
significant itch relief across the body at Week 8 vs vehicle1,3
Greater itch improvement experienced within 24 hours after first application across the scalp and body with ZORYVE vs vehicle (both SI-NRS and WI-NRS, P<0.05)7||
||Measured by mean change from first application in daily SI-NRS/WI-NRS. P-value for WI-NRS is nominal.
In a global survey, ITCH was the #1 most bothersome symptom reported by patients with psoriasis8**
** A 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) telephone survey of 3426 patients ≥18 years old diagnosed with
psoriasis and/or psoriatic arthritis by a healthcare provider. 79% of patients had psoriasis alone.
Request a
Representative